A recent review explores the current understanding of the molecular effects of ruxolitinib and its place in the evolving landscape for the treatment of myeloproliferative neoplasms (MPNs).
Myeloproliferative neoplasms are linked by activation of cytokine-independent signaling through the Janus kinase/signal transducers and activators of transcription (JAK/STAT) cascade. Ruxolitinib, a tyrosine kinase inhibitor (TKI) that inhibits JAK1 and JAK2, is approved for use in intermediate- to high-risk patients with the MPNs primary myelofibrosis (MF) and polycythemia vera (PV) who are resistant to or intolerant of other treatment options. A recent review describes the current understanding of the clinical and molecular effects of ruxolitinib in MPNs, as well as the future of improved therapy for MPNs in the era of JAK inhibition.
Ruxolitinib has shown efficacy in reducing spleen volume and symptom burden versus other available treatments. However, the efficacy of the drug is variable across MPNs, and transformations to secondary MF and acute leukemia have been observed in patients receiving the drug. In MF, the treatment improves the odds of stabilization of bone marrow fibrosis and reduces the chance of worsening fibrosis in some patients, but it does not produce disease reversal, suggesting the need for further advancements in therapies.
Developing such therapies will require better understanding the genomic complexity of MPNs. A range of genes are found to be mutated in patients with MPNs; cooperating oncogenic mutations found alongside driver mutations may impact on disease phenotype and prognosis. The driver mutation JAK2 V617F is understood to result in higher thrombotic risk, for example, while the calreticulin gene (CALR) driver mutation appears to carry a lower risk of thrombosis and has been linked with better overall survival.
Mutated cooperating oncogenes also have important roles; in primary MF, mutations in the genes ASXL1, EZH2, SRSF2, for example, have been observed to independently predict shortened survival. Better understanding such molecular markers will help to provide individualized prognosis for patients, and to understand phenotype as well as thrombosis and transformation risk. “It is in this spectrum of disease that the role of [JAK inhibition and ruxolitinib] in particular will need to be defined,” write the authors, noting that molecular data from clinical trials of ruxolitinib is limited.
Another key issue for further investigation is the fact that MPN clones can persist despite JAK inhibition. This persistence may be because TKI therapy allows resistance to TKIs to develop. Another potential mechanism of resistance to ruxolitinib is recruitment of alternative cell signaling pathways. Reduced DNA repair mechanisms may also allow for clonal selection during ruxolitinib monotherapy.
Furthermore, JAK inhibition may not be able to overcome the effects of histone modification—a key mechanism of epigenetic regulation that can enhance or repress gene transcription—so the role of combined epigenetic manipulation and JAK inhibition should be explored in trials.
Finally, inflammation is linked with neoplastic disease, and patients with MPNs have been shown to have higher levels of circulating cytokines. Ruxolitinib has shown good efficacy in an anti-inflammatory role, and this effect could be augmented through the use of Bromodomain and Extra-Terminal motif (BET) inhibitors. BET inhibition together with ruxolitinib has also been shown to result in reversal of bone marrow fibrosis and a reduction of disease burden.
JAK inhibition “has demonstrated good efficacy in symptom relief but more limited impact on disease modification,” conclude the authors. “Understanding how [JAK inhibition] affects and is affected by each of the key features of pathogenesis…is key to understanding how best to augment this therapy and establish an optimal therapeutic approach to this complex disease state.”
Reference
Greenfield G, McPherson S, Mills K, McMullin MF. The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms. J Transl Med. 2018;16: 360. doi: 10.1186/s12967-018-1729-7.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More